



Open Access Journal by MDPI

Drugs and Drug Candidates

A red-tinted microscopic image showing several large, circular cells with distinct cell walls and internal structures, set against a dark red background.

[mdpi.com/
journal/
ddc](https://mdpi.com/journal/ddc)



Message from the Editor-in-Chief

Drugs and Drug Candidates is an open access initiative of MDPI (Basel, Switzerland). Do you wish to share your knowledge on marketed or newly approved drugs for human or veterinary use? Do you wish to disseminate your recent results on the search for novel promising drug candidates? Our journal, animated by a young and dynamic team, is the ideal platform! Your submission, carefully followed by an academic editor, will be peer-reviewed by experts in the field of the work and a first decision will be notified within no more than two weeks.

Involved in drug design, drug synthesis, drug evaluation, or drug market, *Drugs and Drug Candidates* is of worthy recognition and value.

I look forward to handling your contributions in the very near future. Should you need any information, do not hesitate to contact us.

Editor-in-Chief

Dr. Jean Jacques Vanden Eynde

Aims

Drugs and Drug Candidates is an international scientific journal covering all critical steps involved in the story of a marketed or potential therapeutic agent.

We aim to offer a comprehensive overview of the scientific approaches used in the development of successful drugs and the search for new promising candidates. Chemistry is the main focus of the journal, although other aspects of drug sciences are also addressed. Reviews, research articles, and other formats will be considered, provided they are supported by solid scientific background and appropriate literature references.

Scope

This multidisciplinary journal welcomes submissions describing known drugs for human and veterinary use, as well as efforts to discover and develop new leads. Subjects within the scope of *Drugs and Drug Candidates* include:

- Reviews of marketed drugs
- Reviews of FDA and EMA recently approved drugs
- Virtual design and screening (molecular docking, artificial intelligence, etc.)
- Chemical synthesis and methodologies
- In vitro evaluation and high-throughput screening
- In vivo evaluation and animal models
- Drug delivery
- Intellectual property and regulatory affairs
- Market analysis

Author Benefits

Open Access

Unlimited and free access for readers

No Copyright Constraints

Retain copyright of your work and free use of your article

Thorough Peer-Review

Discounts on Article Processing Charges (APC)

If you belong to an institute that participates with the MDPI Institutional Open Access Program

No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures or colors

Rapid Publication

A first decision is provided to authors approximately 22.4 days after submission; acceptance to publication is undertaken in 6.6 days (median values for papers published in this journal in the second half of 2023)

MDPI is a member of

CASPA



STM¹



SPARC*
Europe



DOAJ



ORCID



Editorial Office

ddc@mdpi.com

MDPI

St. Alban-Anlage 66

4052 Basel, Switzerland

Tel: +41 61 683 77 34

mdpi.com

